ICER evaluates medical treatments, drug prices, and health care access through evidence-based assessments and policy analysis

The Institute for Clinical and Economic Review (ICER) provides independent evaluations of medical tests, treatments, and delivery systems, with a focus on health care affordability, access, and future innovation. Its listed work includes assessments of treatment-resistant depression, Huntington’s disease, Friedreich’s ataxia, hypertension, Parkinson’s disease, and drug pricing and access. ICER also prepares special reports for CMS drug price negotiations, analyzes launch prices for recently approved medicines, and develops policy proposals related to the FDA’s accelerated approval pathway. The organization reports that its analyses have informed Medicaid negotiations and helped save New York more than $500 million, while also engaging patient groups and promoting diversity in clinical trials. The supplied material does not identify a psychedelic substance or psychedelic-specific research focus.